Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$24.34
-3.9%
$22.16
$19.10
$29.55
$1.21B1.76539,985 shs1.30 million shs
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$11.55
-1.1%
$11.42
$9.76
$19.22
$332.03M0.85397,990 shs377,908 shs
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$7.11
-0.6%
$6.57
$5.47
$10.14
$1.06B1.79873,588 shs310,344 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$10.82
+1.5%
$16.59
$9.98
$47.60
$720.29M1.462.65 million shs2.13 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-3.87%+7.32%+15.68%+3.18%-6.02%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-1.11%+6.75%+1.94%-12.37%+17.50%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
-0.56%+1.28%+5.96%+0.85%+15.61%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
+1.50%-3.65%-31.30%-53.12%-74.06%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.1951 of 5 stars
3.63.00.00.03.12.50.6
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.8903 of 5 stars
3.51.00.00.02.20.80.6
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.1977 of 5 stars
3.54.00.00.03.21.70.6
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.5752 of 5 stars
4.13.00.04.92.71.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
3.13
Buy$31.2928.54% Upside
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$19.6770.27% Upside
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
3.00
Buy$12.0068.78% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.20
Hold$22.67109.49% Upside

Current Analyst Ratings Breakdown

Latest CLPT, MDXG, TNDM, and BLFS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/11/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$75.00 ➝ $12.00
8/8/2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$30.00 ➝ $32.00
8/8/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$53.00 ➝ $51.00
8/7/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$59.00 ➝ $24.00
8/7/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral$30.00 ➝ $14.00
8/7/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $17.00
8/7/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $13.00
8/7/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$45.00 ➝ $25.00
8/1/2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
7/31/2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$11.00 ➝ $12.00
(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
$82.25M14.17$0.12 per share206.67$7.25 per share3.36
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$31.39M10.46N/AN/A$0.69 per share16.74
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$348.88M3.02$0.33 per share21.58$1.46 per share4.87
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$940.20M0.78N/AN/A$1.97 per share5.49
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$20.18M-$0.12N/AN/AN/A-5.39%0.16%0.14%N/A
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$18.91M-$0.81N/AN/AN/A-66.15%-94.44%-51.58%N/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$42.42M$0.2133.8622.22N/A8.84%23.03%17.09%10/29/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%N/A

Latest CLPT, MDXG, TNDM, and BLFS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.20-$0.21-$0.01-$0.21$9.20 million$9.22 million
8/7/2025Q2 2025
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
-$0.02-$0.33-$0.31-$0.33$23.71 million$25.42 million
8/6/2025Q2 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million
7/30/2025Q2 2025
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
$0.06$0.10+$0.04$0.06$90.79 million$98.61 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
N/AN/AN/AN/AN/A
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
0.03
4.43
3.45
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
1.46
7.30
2.57
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
0.08
4.39
3.90
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.32
2.44
1.88

Institutional Ownership

CompanyInstitutional Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
93.24%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
79.15%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
2.20%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.97%
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
1.70%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLife Solutions, Inc. stock logo
BLFS
BioLife Solutions
44047.90 million46.85 millionOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11028.43 million26.45 millionOptionable
MiMedx Group, Inc stock logo
MDXG
MiMedx Group
870147.96 million145.44 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,65067.57 million66.29 millionOptionable

Recent News About These Companies

Tandem Diabetes Care (NASDAQ:TNDM) Cut to "Hold" at Lake Street Capital
Tandem Diabetes Care Gains FDA Clearance for SteadiSet

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLife Solutions stock logo

BioLife Solutions NASDAQ:BLFS

$24.34 -0.98 (-3.87%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$24.59 +0.25 (+1.03%)
As of 08/15/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides cryogenic freezer technology for controlled rate freezing and cryogenic storage of biologic materials; ultra-low temperature mechanical freezers; evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage and transport services. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.

ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$11.55 -0.13 (-1.11%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$11.54 -0.02 (-0.13%)
As of 08/15/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

MiMedx Group stock logo

MiMedx Group NASDAQ:MDXG

$7.11 -0.04 (-0.56%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$7.12 +0.00 (+0.07%)
As of 08/15/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$10.82 +0.16 (+1.50%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$10.93 +0.11 (+1.02%)
As of 08/15/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.